10x Genomics (TXG) EBITDA (2018 - 2026)

10x Genomics (TXG) has 9 years of EBITDA data on file, last reported at -$17.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 56.66% year-over-year to -$17.0 million; the trailing twelve-month figure through Mar 2026 stood at -$38.7 million (up 77.55% YoY), and the FY2025 full-year result was -$61.0 million, up 68.65% from the prior year.
• EBITDA grew to -$17.0 million in Q1 2026, from -$19.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $30.1 million in Q2 2025 to a low of -$94.8 million in Q3 2023.
• A 5-year average of -$41.5 million and a median of -$41.7 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA tumbled 511.13% in 2022 and surged 172.18% in 2025, its largest moves.
• Tracing TXG's EBITDA over 5 years: stood at -$23.1 million in 2022, then tumbled by 138.95% to -$55.2 million in 2023, then grew by 9.69% to -$49.8 million in 2024, then surged by 60.79% to -$19.5 million in 2025, then gained by 12.77% to -$17.0 million in 2026.
• Business Quant data shows TXG's EBITDA at -$17.0 million in Q1 2026, -$19.5 million in Q4 2025, and -$32.2 million in Q3 2025.